Compare · ELV vs GH
ELV vs GH
Side-by-side comparison of Elevance Health Inc. (ELV) and Guardant Health Inc. (GH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and GH operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $92.91B, about 4.2x GH ($22.26B).
- GH has been more active in the news (18 items in the past 4 weeks vs 3 for ELV).
- GH has more recent analyst coverage (25 ratings vs 23 for ELV).
- Company
- Elevance Health Inc.
- Guardant Health Inc.
- Price
- -
- -
- Market cap
- $92.91B
- $22.26B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 3
- 18
- Recent ratings
- 23
- 25
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Guardant Health Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Latest ELV
- SEC Form 4 filed by Elevance Health Inc.
- Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026
- Elevance Health’s Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- EVP & Chief Legal Officer Wessling Erin M covered exercise/tax liability with 349 shares, decreasing direct ownership by 5% to 7,230 units (SEC Form 4)
- EVP & Chief HR Officer Craig Ryan R covered exercise/tax liability with 144 shares, decreasing direct ownership by 2% to 6,530 units (SEC Form 4)
- Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
Latest GH
- SEC Form 4 filed by Guardant Health Inc.
- TwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent
- Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
- SEC Form 144 filed by Guardant Health Inc.
- SEC Form 4 filed by Guardant Health Inc.
- Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
- Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
- Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
- Chief Legal Officer Saia John G. converted options into 7,063 shares and covered exercise/tax liability with 3,706 shares, increasing direct ownership by 9% to 42,348 units (SEC Form 4) (withholding obligation)
- Chief People Officer Monroe Terilyn J. converted options into 4,019 shares and covered exercise/tax liability with 2,098 shares, increasing direct ownership by 8% to 24,900 units (SEC Form 4) (withholding obligation)